Table 1 (abstract P195). Biologic medication according to JIA cathegory.
From: Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018)
Type of medication | Registrations* | Systemic JIA* | Poly (RF neg) JIA* | Poly (RF pos) JIA* | Oligo (persistent) JIA* | Oligo (extending) JIA* | Enthesitis related JIA* | Psoriatic JIA* | Undifferentiated JIA* |
|---|---|---|---|---|---|---|---|---|---|
Registrations, total | 1047 (100) | 231 (21) | 363 (35) | 98 (9) | 113 (11) | 138 (13) | 66 (6) | 31 (3) | 7 (1) |
Etanercept | 490 (47) | 34Â (7) | 177Â (36) | 63 (13) | 45 (9) | 94 (19) | 54 (11) | 21 (4) | 2 (0.4) |
Infliximab | 91 (9) | 10 (11) | 34 (37) | 12 (13) | 24 (26) | 4 (4) | - | 4 (4) | 3 (3) |
Adalimumab | 219 (21) | 15 (7) | 104 (48) | 15 (7) | 41 (19) | 24 (11) | 12 (6) | 6 (3) | 2 (1) |
Anakinra | 45 (4) | 42 (93) | 3 (7) | - | - | - | - | - | - |
Tocilizumab | 155 (15) | 109 (70) | 34 (22) | 6 (4) | 1 (0.6) | 5 (3) | - | - | - |
Abatacept | 24 (2) | 6 (25) | 7 (29) | 2 (8) | 2 (8) | 7 (29) | - | - | - |
Other | 26 (2) | 18 (69) | 4 (15) | - | - | 4 (15) | - | - | - |